Szostak, B. (2025) “Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?”, Prospects in Pharmaceutical Sciences, 23(2), pp. 42–49. doi: 10.56782/pps.361.